(OCR) 銘柄情報

A $2M purchase on Friday is a great sign. We're pushing $55 by end of summer here. Keep your eyes open.

~ Thursday! $OCR ~ Earnings posted, pending or coming soon! In Charts and Links Below!

~ $OCR ~ Earnings expected on Thursday *
Want more like this? Search Keyword: MACMONEY >>> http://tinyurl.com/MACMONEY <<<
One or more of many earnings sites has alerted this security has or will be posting earnings on or around the day of this message.








http://stockcharts.com/h-sc/ui?s=OCR&p=D&b=3&g=0&id=p88783918276&a=237480049




http://stockcharts.com/h-sc/ui?s=OCR&p=W&b=3&g=0&id=p54550695994



~ Google Finance: http://www.google.com/finance?q=OCR
~ Google Fin Options: hhttp://www.google.com/finance/option_chain?q=OCR#
~ Yahoo! Finance ~ Stats: http://finance.yahoo.com/q/ks?s=OCR+Key+Statistics
~ Yahoo! Finance ~ Profile: http://finance.yahoo.com/q/pr?s=OCR
Finviz: http://finviz.com/quote.ashx?t=OCR
~ BusyStock: http://busystock.com/i.php?s=OCR&v=2


<<<<<< http://www.earningswhispers.com/stocks.asp?symbol=OCR >>>>>>



http://investorshub.advfn.com/boards/post_prvt.aspx?user=251916

*If the earnings date is in error please ignore error. I do my best.

PharMerica comments on Omnicare's decision to allow its unsolicited tender offer to expire; says 'Omnicare's (OCR) offer substantially undervalued PharMerica and was illusory due to the significant antitrust concerns' (PMC) 12.79 -0.22 : 'We are pleased with Omnicare's decision to allow its tender offer to expire. The PharMerica Board of Directors was unanimous in its belief that Omnicare's offer substantially undervalued PharMerica and was illusory due to the significant antitrust concerns. PharMerica has continued to perform well, as exemplified by our strong fourth quarter earnings, and we are well positioned for further growth as the wave of generic drug conversions continues to accelerate. We remain focused on executing our strategic plan and exceeding our customers' expectations as we work to deliver compelling value to PharMerica stockholders.'

OCR HOD 26.7 - 27% gain

HOD 24.14

-15%

5 mil vol

OCR @ 21.04

PharMerica Board unanimously rejects unsolicited conditional tender offer from Omnicare (OCR) (PMC) 14.39 -0.24 : PMC announced that its Board of Directors, after careful consideration with its independent financial and outside legal advisors, voted unanimously to reject the unsolicited tender offer made by Omnicare (OCR) to acquire PMC for $15.00 per share in cash. The Board determined that the offer undervalues PharMerica and is not in the best interests of PharMerica's stockholders. In addition to undervaluing PharMerica and its future prospects, the Board believes the offer is illusory because it is subject to significant regulatory and other uncertainty. The Board unanimously recommends that PharMerica stockholders reject Omnicare's offer and not tender their shares to Omnicare.

PharMerica gets buyout offer from Omnicare
Tampa Bay Business Journal
Date: Tuesday, August 23, 2011, 5:18pm EDT
Related:
Health Care, Pharmaceuticals

PharMerica Corp. PharMerica Corp. Latest from The Business Journals Omnicare CEO: PharMerica bid isn't hostilePharMerica board rebuffs 6M Omnicare bidOmnicare makes 6M offer for PharMerica Follow this company said it received and rejected an unsolicited buyout proposal from Omnicare Inc. Omnicare Inc. Latest from The Business Journals Omnicare CEO: PharMerica bid isn't hostilePharMerica board rebuffs 6M Omnicare bidOmnicare makes 6M offer for PharMerica Follow this company

The transaction would be valued at $716 million, including PharMerica’s debt, Omnicare said.

PharMerica (NYSE: PMC) is a Louisville, Ky.-based institutional pharmacy services company with a major operations center in Tampa.

PharMerica’s board of directors determined the Omnicare offer of $15 a share in cash undervalues PharMerica and was not in the best interest of the company or its stockholders, a company statement from PharMerica said.

In its own statement, Omnicare said the proposal represents a 37.2 percent premium over PharMerica’s closing stock price on Aug. 22 and a 25.9 percent premium over the average closing price for the one-months period ended Aug. 22. In a separate statement, Omnicare said the proposal offered a “compelling value proposition” for PharMerica stockholders and said it was committed to pursuing the deal.

Omnicare (NYSE: OCR), headquartered in Covington, Ky., provides pharmaceutical services to patients and providers across North America.

Karen on Fast Money says she likes the stock.

Trueheart

*Latest OMNICARE INC News* LINK* 04/27/11
http://www.dailyfinance.com/rtn/pr/global-health-ventures-to-initiate-discussion-with-omnicare-on-x-excite-vs-viagra-r-trials-in-the-united-states/rfid438623303/?channel=pf

Always....on the watch...thank you!

may contract again . keep it on watch .

I missed out on this one....I am kicking myself. It's a great company well worth the investment..)

Hope y'all got in 2 days ago... it wants $31 IMO.

Entry to be considered IMO.

Not bottom yet.